Table 1.
Personal information and clinical characteristics of 7 patients with COVID-19
| Characteristics | case1(patient1) | case2(patient2) | case3(patient3) | case4(patien4) | case5(patient5) | case6(patient6) | case7(patient7) |
|---|---|---|---|---|---|---|---|
| Age (years) | 49 | 38 | 10 | 75 | 43 | 41 | 18 |
| Sex | male | female | male | male | male | female | female |
| Hospitalization days | 16 | 12 | 6 | 38 | 9 | 8 | 14 |
| Time from illness onset to first hospital admission (days) | 7 | 6 | 9 | 4 | 6 | 7 | 6 |
| Disease severity | common | mild | mild | severe | common | common | mild |
| Coexisting disorders | – | – | – | Bronchiectasis Obsolete tuberculosis Postoperative esophageal cancer | Pneumoconiosis | – | – |
| Smoking histrory | – | – | – | 20 years>400pcs/year | 20 years>400pcs/year | – | – |
| Drinking history | – | – | – | 10 years,200 ml/Day | – | – | – |
| Treatment | |||||||
| Antibiotic treatment | – | Moxifloxacin | – | Moxifloxacin Meropenem Piperacillin - tazobactam sodium Fluconazole | – | – | – |
| Antiviral therapy | Interferon alpha inhalation Lopinavir/ritonavir | Interferon alpha inhalation;Lopinavir/ritonavir | Interferon alpha inhalation;Lopinavir/ritonavir |
Interferon alpha inhalation Lopinavir/ritonavir Arbidol Chloroquine phosphate |
Interferon alpha inhalation Lopinavir/ritonavir | Interferon alpha inhalation Lopinavir/ritonavir; Arbidol | Interferon alpha inhalation Lopinavir/ritonavir |
| Chinese patent medicine treatment | Traditional Chinese medicine | Traditional Chinese medicine Tanreqing Xiyanping | Traditional Chinese medicine | Traditional Chinese medicine | Traditional Chinese medicine | Traditional Chinese medicine | Traditional Chinese medicine |
| Oxygen therapy | |||||||
| Air | yes | yes | yes | no | yes | yes | yes |
| Nasal catheter | – | – | – | 2 L/min | – | – | – |
| High flow oxygen | – | – | – | – | – | – | – |
| Non-invasive ventilator | – | – | – | – | – | – | – |
| Invasive ventilator | – | – | – | – | – | – | – |
| Days of immune booster use | 1 week | – | – | 2 week | – | – | – |
| Convalescent plasma therapy | – | – | – | Intravenous infusion of convalescent plasma 5 times, totaling 1000 ml | – | – | – |
| Nucleic acid recovery positive | yes | – | – | – | – | – | – |
| Admission to intensive care unit | – | – | – | Admission on day 28 and discharge on day 35 | – | – | – |
| Anxiety, depression | Psychological counseling | – | – | Psychological counseling | – | – | – |
| Discharge from hospital | |||||||
| Death | – | – | – | – | – | – | – |
| Recovery | yes | yes | yes | yes | yes | yes | yes |